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BK polyomavirus virus hemorrhagic cystitis
following allogeneic bone marrow transplant with
haploidentical related donor: case reports from two
patients
Abstract

Volume 2 Issue 4 - 2017

BK virus is well known to be associated with allograft failure in renal transplant
recipients due to polyomavirus-associated nephropathy (PVAN). BK viruses
are increasingly recognized an important cause of hemorrhagic cystitis during
hematopoietic stem cell transplantation (HSCT). Here we describe two patients
with acute lymphoblastic leukemia who received a haplo identical match related
donor hematopoietic stem cell transplant after myeloablative conditioning and posttransplant cyclophosphamide. They developed cytology proven BK Virus cystitis. Both
were treated with Leflunomide. Treatment was effective in alleviating the symptoms
temporarily but eventually the symptoms progressed and resulted in mortality of both
patients.

Danish Shakeel, Natasha Ali, Mohammad
Usman Shaikh, Salman Naseem Adil

HSCT, hematopoietic stem cell transplantation; PML, progressive
multifocal leukoencephalopathy

Introduction
Hemorrhagic cystitis is a common complication in allogeneic
bone marrow transplant recipients.1 The association of BK virus
cystitis and allogeneic bone marrow transplant was first described
two decades ago.2 The incidence of hemorrhagic cystitis in allogeneic
bone marrow transplant patients is reported up to 70%, while BK
viruria after allogeneic bone marrow transplant is detected in 50 to
100% of the patients.1–6 Hemorrhagic cystitis is a cause of significant
morbidity following allogeneic bone marrow transplant. Many factors
have been implicated in the etiology including the toxic effects of
the chemotherapeutic drugs and viral infections. The most common
viruses associated with hemorrhagic cystitis in both children and adults
are BK virus, cytomegalovirus (CMV) and adenovirus.1,3,7,8 Among
immunocompromised patients, only two strains of polyomaviruses
have been proven to cause disease. Polyomavirus hominis 1 (BK
virus) causes cystitis, nephritis and polyomavirus hominis 2 (JC
virus) causes multifocal leukoencephalopathy (PML). The prevalence
of BK virus increases with intense immunosuppressive therapy
and it is probably the most common cause of hemorrhagic cystitis
in allogeneic hematopoietic stem cell transplant (allo - HSCT)
recipients.9 The mainstay of treatment in these patient is reducing
the dose of immunosuppressive therapy, bladder irrigation, anti-viral
agents and monitoring of BK virus in urine and blood. Up till now only
few reports have attributed the role of BK virus in the pathogenesis
of hemorrhagic cystitis after allo –HSCT.2,9–11 Here we describe two
cases of BK virus hemorrhagic cystitis following allogeneic stem
cell transplant from a haploidentical match related donor. In the
cases discussed below, we used myeloablative-conditioning regimen
along with post transplant cyclophosphamide. This resulted in intense
immunosuppression leading to reactivation of BK virus. We found
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that cytology was useful in the diagnosis of BK virus infection in
urine. Supportive care along with Leflunomide treatment resulted
in improvement of symptoms, however the infection resulted in
prolonged hospital stay and significant morbidity.

Case presentation
Case: 1
A 23-years-old male was diagnosed as precursor B cell acute
lymphoblastic leukemia. The prognostic workup showed normal
bone marrow karyotyping. He was started on HYPER-CVAD
protocol (fractionated cyclophosphamide, vincristine, doxorubicin,
and dexamethasone) through which he achieved remission. During
the maintenance phase, he developed CNS relapse, which was
confirmed by CSF detailed report (DR) and cytology showing
95% blast cells. Re-induction was attempted through FLAG-IDA
protocol (fludarabine, idarubicin, cytarabine) along with intra-thecal
chemotherapy, following which, the G-CSF, DR and cytology became
negative. Bone marrow examination after induction chemotherapy
was in morphological remission. Patient underwent allogeneic bone
marrow transplant with blood group matched and sex-matched
haplo-indentical related donor. Prior to transplant, patient’s CMV
IgM antibody and CMV PCR was positive. He therefore received
treatment with valgancicylovir. Conditioning regimen included antithymocyte antiglobin (Rabbit-ATG, FRESENIUS) at 10mg/kg from
day -8 to day -6, fludarabine 30mg/m2 from day -7 to day -2, low
dose total body irradiation (200cGy) once daily from day -5 to day -4
and cyclophosphamide 50mg/kg from day -3 to day -2. For GVHD
prophylaxsis cyclophosphamide 50mg/kg was given on day +3, day +4
and mycophenolate mofetil (MMF) along with tacrolimus was started
from day + 5. Dose of Tacrolimus was adjusted as required to keep
trough level between 10 to 15ng/ml. Myeloid engraftment occurred
on day +19. On day +27 patient developed burning micturation,
dysuria and frank hematuria. Urine DR showed red blood cells of
more than 20 per high power field (HPF) and hemoglobin of more
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than 150 per microlitre. Ultrasound revealed, thick walled urinary
bladder (approximately 5mm), most likely secondary to cystitis.
Patient’s coagulation profile was normal, blood and urine cultures
were negative. Cytospin preparation of urine revealed inflammatory
cells predominantly neutrophils along with urothelial cells. Cells
with large, round, homogenous, blue, black inclusion in the nucleus
were also identified. Since our laboratory does not perform BK virus
PCR, a diagnosis of BK virus cystitis was made through cytology and

129

patient was managed with fluid hydration, bladder irrigation and antiviral therapy (Leflunomide). The treatment, the patient’s symptoms
improved with negative urine cytology repeated on day +37 and day
+56. However patient presented again on day +100 with hematuria
along with transplant related Thrombotic Thrombocytopenic Purpura,
MRSA (methicillin-resistant Staphylococcus aureus) bacteremia
& multiorgan failure. He eventually succumbed to his illness on
day+109 (Table 1) (Table 2) (Figure 1).

Table 1 Different diagnostic techniques available for diagnosis of BK virus infection
Screening method

Positive predictive value (%)

Negative predictive value (%)

Sensitivity (%)

Specificity (%)

Decoy cells(14,18)

29

100

25

84

BK urine PCR(14,18)

40

100

100

78

BK serum PCR(14,18)

50-60

100

100

88

Table 2 Treatment options for BK virus hemorrhagic cystitis2,7,10,14
Name of drug

Class of drug

Mechanism of action

Reported side effects

Effectiveness

Leflunomide

Malononitrilamides

Inhibition of pyrimidine
synthesis & tyrosine kinases

Rash, alopecia, Thrombocytopenia,
Pancytopenia, Thrombotic
microangiopathy

Doubtful, modest antiviral
effect in vitro

Cideofovir

Nucleotide analogue

Inhibition of viral replication
by unknown mechanisms.
Inhibition of DNA polymerase
activity of large T antigen

Headache, Nephrotoxicity, Anterior
uveitis, Neutropenia

Doubtful, mostly case reports
have shown variable results

Ciprofloxacin

Fluoroqinolone

Inhibition of polyomavirus
T-antigen helicase activity

Rash, Diarrhea, Nausea, Dizziness,
Headache, Restlessness, Resistance

Doubtful, likely more effective as
prophylactic agent

IVIg

Immunomodulatory

Antibody mediated
neutralization

Paradoxical rise in viral load

Doubtful

Case: 2

Figure 1 Panel A and B shows Cytospin preparation (100x) of urine sample
from patient 1 revealed inflammatory cells predominantly neutrophils along
with urothelial cells. Cells with large, round, homogenous, blue, black inclusion
in the nucleus were also identified. Panel C and D shows Cytospin preparation
(100x) of urine sample from patient 2 revealed squamous epithelial cells
and urothelial cells along with neutrophils, red blood cells, histiocytes and
macrophages. Few cells showing large homogenous, even nuclei and BK virus
inclusions.

A 19-years-old male was diagnosed with T cell acute lymphoblastic
leukemia and complex bone marrow karyotype. Patient was started
on MRC UKALL XII protocol and relapsed after First cycle of
consolidation, which was confirmed by bone marrow trephine biopsy.
Patient was given re-induction chemotherapy with FLAG-IDA
protocol, following which he achieved morphological remission.
He underwent allogeneic HSCT with haplo-identical related donor
(mother) having minor blood group mismatch. Prior to transplant his
CMV serology was positive for IgG. Conditioning regimen included
anti-thymocyte antiglobin (Rabbit-ATG, FRESENIUS ) at 10mg/kg
from day -8 to day -6, fludarabine 30mg/m2 from day -7 to day -2,
low dose total body irradiation (200cGy) once daily from day -5 to
day -4 and cyclophosphamide 50mg/kg from day -3 to day -2. GvHD
prophylaxis was similar to that of previous case. This patient also
received post-transplant cyclophosphamide on day +3 and +4 (50mg/
kg). Myeloid engraftment occurred on day +17. Patient was readmitted on day +50 with gross hematuria and passage of clots during
mictuiration. He had persistently decreased hemoglobin while urine
DR showed red blood cells of more than 20/HPF, hemoglobin more
than 250 per microlitre. Thick-walled urinary bladder (approximately
1.04cm) with large intra luminal blood clot (approximately 9x8x6cm)
was reported on ultrasound. Patient’s coagulation profile was
normal. His urine culture grew ESBL (Extended spectrum betalactamases) Escherichia coli. Cytospin preparation of urine showed
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squamous epithelial cells and urothelial cells along with neutrophils,
red blood cells, histiocytes and macrophages. Few cells showing
large homogenous nuclei with inclusions were seen on his cytospin
preparation. A diagnosis of BK Virus cystitis was made. Patient was
managed with fluid hydration, sensitive intra venous antibiotic, bladder
irrigation, anti-viral (Leflunomide) and irradiated blood products
transfusion. With treatment hematuria improved but patient expired
on day +108 due to secondary graft failure, sepsis and peritonitis.

Discussion
BK virus was first isolated in 1971 by Gardner and co-workers
in the urine sample of a patient who presented with renal failure
following kidney transplant. They named the virus after the initials of
this patient. BK virus is a non-encapsulated DNA virus that is prevalent
in about 90 to 100% of the population. The virus is transmitted via
upper respiratory tract, during the early childhood. Following initial
infections the virus can remain latent in the renal urothelium and
other organs for entire life.3,5,7 Primary infection is asymptomatic or
occasionally causes mild self-limiting upper respiratory infection.
Disease caused by latent polyomaviruses is typically not seen in the
immunocompetent host. During periods of immunosuppression, such
as following solid organ or hematopoietic stem cell transplantation,
BK virus reactivation may lead to organ dysfunction. These conditions
are characterized by the shedding of viral particles and viral inclusion
bearing epithelial cells into the urine and are known as decoy cells.
The cells are produced due to massive replication of BK virus in the
mucosal layer of urinary bladder resulting in inflammation of bladder
wall. Cystitis occurs several weeks after allogeneic bone marrow
transplant. Thus examination of urine cytology specimens to search
for polyomavirus inclusion bearing cells is an important clinical tool
to assess the reactivation of this condition in HSCT recipients.12,13
However, cytology has some limitations; such as these decoy cells
can be confused with malignant cells and similar cytopathology can
result from infections with other viruses e.g. JC virus and adenovirus.
The sensitivity of decoy cells is only 25% with a specificity of 84%.
However absence of decoy cells in urine has a negative predictive
value of 100%. Therefore, detection of BK virus DNA in the urine
by PCR remains the modality of choice with a sensitivity of 100%.
Biopsy of renal urothelium is gold standard for detection of BK
virus. The diagnosis is based on immunohistochemical stains.2,14
A study done by Gore et al.14 described various risk factors for the
development of BK virus cystitis, the most important being the degree
of immunosuppression. Other factors included male gender, old age,
rejection episodes, degree of HLA disparity, BK virus serostatus prior
to transplant and prolong limb ischemia.2,14 BK virus activation after
allogeneic bone marrow transplant is associated with manifestations
ranging from asymptomatic viruria to severe hemorrhagic cystitis,
ureteral stenosis and interstitial nephritis. Hemorrhagic cystitis is
the most prevalent of these complications and occurs in 10–25% of
patients due to the inflammation of bladder wall. Patients present with
dysuria, frequency of urination and suprapubic pain. The latter was
present in our second patient. The severity of the pain was high on
pain scale since he required continuous patient controlled analgesic
for relief. Hematuria is variable and the severity of hematuria can be
assessed by using a grading system which was proposed by Droller
et al.15 According to this grading system, grade 0 is no symptoms
of bladder irritability or hemorrhage, grade 1 is microscopic
hematuria, grade 2 is macroscopic hematuria, grade 3 is macroscopic
hematuria with clots and grade 4 is Massive macroscopic hematuria
requiring instrumentation for clot evacuation and/or causing urinary
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obstruction. Both our patients had grade 4 hematuria; the second
patient required cystoscopy for clot removal. BK virus hemorrhagic
cystitis can also result in renal failure and prolong hospital stay.
Both our patients had multiple hospital admissions, which required
long stays for the treatment of underlying symptoms. Although it is
rarely life threatening BK virus cystitis is associated with significant
morbidity.2,15 The mortality in our patients occurred due to different
causes, but the associated complaint of BK virus cystitis contributed
significantly to the morbidity.
In general, treatment of BK virus hemorrhagic cystitis is
supportive and includes measures that are directed to control bleeding.
Maintaining a platelet count above 50x109/L and a hematocrit of 25%
in patients with≥ grade 2 hematuria can be beneficial. Mild cases
resolve spontaneously within few weeks. Clot formation in bladder
can occur in severe cases, which may result in obstruction. In these
situations, cystoscopy for clot evacuation and possible cauterization
may be helpful to preserve renal function.2 We carried out the same
procedure in our second patient who had persistence of clots in the
bladder. The mainstay in the management of BK virus hemorrhagic
cystitis is reduction in the immunosuppression. This can be done
by either switching tacrolimus to cyclosporine or discontinuing the
immunosuppressive agent. Another effective strategy is reduction
in the dose of immunosuppressive agents by 25 to 50%, which
can be further guided by the trough level of the drug. The aim is
to maintain a significantly lower trough level (tacrolimus 3-4ng/
mL and cyclosporine 50–100ng/mL, or even less).14 Sood et al.16
concluded that reduction in immunosuppression alone resulted in the
successful resolution of viremia with preservation of renal function
and prevention of clinical BKV nephritis and graft loss in significant
number of patients.16 We stopped immunosuppression in both our
patients. The symptoms did not resolve in one while bone marrow
suppression occurred in both. Leflunomide belongs to the class
of drugs called malononitrilamides. It works by inhibiting protein
kinase activity and pyrimidine synthesis. Leflunomide has antiviral
activity in vitro against CMV, herpes simplex virus and BK virus. The
drug has been used in allogeneic bone marrow transplant recipients
for the treatment of resistant/refractory BK virus infections with
variable success.2 Both our patients partially responded to this antiviral therapy. Nicole N et al.17 evaluated the role of leflunomide for
treatment of biopsy proven BK virus nephropathy. The results showed
that 71% of patients receiving leflunomide (at least 60 mg daily) along
with reduction in immunosuppression cleared the virus.17

Conclusion
In conclusion, BK virus infection is a serious and increasingly
recognized complication in bone marrow transplant recipients. It is
associated with significant morbidity and a prolonged hospital stay.
Bone marrow transplant centers should develop a protocol for BK virus
surveillance, treatment, and monitoring. Cytological examination of
urine is a helpful test for diagnosis of BK virus cystitis, but it has
limitations. However newer laboratory based assays may develop
in future, making the diagnosis easier. The mainstay of treatment
remains careful reduction of immunosuppression, bladder irrigation,
blood products transfusion and anti-viral agents.18
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